Agrylin (Anagrelide Hydrochloride) - Summary

AGRYLIN SUMMARY

AGRYLIN®
(anagrelide hydrochloride)
Capsules

Rx only

AGRYLIN® (anagrelide hydrochloride) reduces blood platelet count.

AGRYLIN® Capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events (see CLINICAL STUDIES, DOSAGE and ADMINISTRATION).

See all Agrylin indications & dosage >>

AGRYLIN NEWS HIGHLIGHTS

Published Studies Related to Agrylin (Anagrelide)

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. [2005.07.07]

[Anagrelide for treatment of patients with essential thrombocythaemia] [2008.05]

TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders. [2008.04.13]

[Appearance of leg ulcers associated with intake of anagrelide] [2007.02.16]

Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. [2007]

more >>

Clinical Trials Related to Agrylin (Anagrelide)

Fed Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg [Completed]

Fasting Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg [Completed]

A Phase II Study of the Pharmacokinetics of Anagrelide in Elderly and Young ET Patients [Recruiting]

A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients [Recruiting]

Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to Xagrid Compared to Other Treatments [Recruiting]

more >>